▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Nektar Therapeutics (NASDAQ: NKTR)

$1.31

(0.8%)

$0.01

Price as of October 9, 2024, 11:45 a.m. ET

Nektar Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
NKTR	+155.00%	-91.94%	-39.57%	-65%
S&P	+32.65%	+95.74%	+14.38%	+1,169%

Nektar Therapeutics Company Info

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

News & Analysis

The Fool has written over 100 articles on Nektar Therapeutics.

Featured Article

Why Nektar Therapeutics Stock Is Crashing Today

The company is throwing in the towel on its lead pipeline program.

Keith Speights | Apr 18, 2022

Featured Article

Why Nektar Therapeutics Stock Is Imploding Today

A clinical trial readout involving the company's lead candidate didn't produce the results investors were hoping for.

Cory Renauer | Mar 14, 2022

Why Nektar Therapeutics Stock Plunged Today

Keith Speights | Nov 5, 2021

The company's Q3 revenue was lower than expected.

3 Stocks Wall Street Thinks Will Soar 50% or More in 2021

Keith Speights | Jan 24, 2021

These stocks have one obvious thing in common.

2 Biotechs Battling Against Kidney Cancer

David Haen | Apr 18, 2020

New combination trials bring hope for patients and investors.

Here's How Nektar Therapeutics Performed in Q4

Keith Speights | Feb 28, 2020

The biotech topped Wall Street estimates, but the real focus was on its pipeline.

FDA Advisory Committee Slams Nektar's New Opioid Drug

Taylor Carmichael | Jan 15, 2020

In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.

Why Nektar Therapeutics Stock Is Sinking Today

Keith Speights | Jan 15, 2020

The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.

Valuation

Podcast Episodes

Can Drugmakers Cure the Opioid Crisis?

Deaths from prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.

Todd Campbell and Kristine Harjes | Apr 18, 2017

Earnings Transcripts

Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript

NKTR earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 4, 2021

Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript

NKTR earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 5, 2021

Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript

NKTR earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | May 7, 2021

Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript

NKTR earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 26, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services